BiotechTube

Goserelin Acetate + Pembrolizumab

Phase 2Recruiting
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Salivary Gland Carcinoma

Conditions

Salivary Gland Carcinoma

Trial Timeline

May 30, 2019 → Aug 1, 2026

NCT ID
NCT03942653

About Goserelin Acetate + Pembrolizumab

Goserelin Acetate + Pembrolizumab is a phase 2 stage product being developed by Merck for Salivary Gland Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT03942653. Target conditions include Salivary Gland Carcinoma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT03942653Phase 2Recruiting

Competing Products

11 competing products in Salivary Gland Carcinoma

See all competitors
ProductCompanyStageHype Score
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
enzalutamideAstellas PharmaPhase 2
52
GefitinibAstraZenecaPhase 2
52
DovitinibNovartisPhase 2
52
Sacituzumab govitecanGilead SciencesPhase 2
51
Nivolumab + IpilimumabBristol Myers SquibbPhase 2
51
Ipilimumab + NivolumabBristol Myers SquibbPhase 2
51
Darolutamide + GoserelinBayerPhase 2
49
IvonescimabSummit TherapeuticsPhase 2
49
CabozantinibIpsenPhase 2
49
AVA6000Avacta GroupPhase 1
25

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85